skip to Main Content

‘Real-world’ experience confirms effectiveness of sofosbuvir/velpatasvir/voxilaprevir in people with chronic hepatitis C (HCV) infection failing direct-acting antivirals (DAAs)

ILC 2019: ‘Real-world’ studies in Germany and the USA confirm high rates of sustained virological response with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in individuals with chronic HCV infection failing DAAs 10 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE…

Read More